KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBITDA (2016 - 2025)

Historic EBITDA for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $196.8 million.

  • Sarepta Therapeutics' EBITDA rose 311527.53% to $196.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $401.5 million, marking a year-over-year increase of 74843.2%. This contributed to the annual value of $218.1 million for FY2024, which is 14088.55% up from last year.
  • Sarepta Therapeutics' EBITDA amounted to $196.8 million in Q2 2025, which was up 311527.53% from $161.7 million recorded in Q4 2024.
  • Over the past 5 years, Sarepta Therapeutics' EBITDA peaked at $196.8 million during Q2 2025, and registered a low of -$515.5 million during Q1 2023.
  • For the 5-year period, Sarepta Therapeutics' EBITDA averaged around -$71.8 million, with its median value being -$48.2 million (2021).
  • Per our database at Business Quant, Sarepta Therapeutics' EBITDA crashed by 88862.75% in 2021 and then soared by 311527.53% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' EBITDA stood at -$122.0 million in 2021, then grew by 11.71% to -$107.7 million in 2022, then surged by 143.83% to $47.2 million in 2023, then soared by 242.46% to $161.7 million in 2024, then grew by 21.73% to $196.8 million in 2025.
  • Its EBITDA stands at $196.8 million for Q2 2025, versus $161.7 million for Q4 2024 and $36.9 million for Q3 2024.